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 CURRENTOPINION Applying ‘Patient Blood Management’ in the
trauma center
Oliver M. Theusinger, Philipp Stein, and Donat R. Spahn
Purpose of review
The purpose of this review is to highlight the use of tranexamic acid, point-of-care testing, algorithm-based
treatment of trauma-associated coagulopathy with factor concentrates to reduce blood loss and transfusion
requirements in order to improve outcome. In addition, the management of patients on new oral
anticoagulants, drugs with renewed interest and the tolerance of relatively low hemoglobin levels in the
context of trauma will be discussed.
Recent findings
Early administration of tranexamic acid reduces mortality without increasing the risk of thromboembolic
events. Point-of-care testing is increasingly recommended. Goal-directed individualized coagulation
algorithms with the use of factor concentrates allow reducing the amount of allogeneic blood products to
be administered. Treatment of trauma patients with one of the new oral anticoagulants is challenging.
Furthermore, new mechanisms have been discovered such as deep neuromuscular blockade to better
tolerate acute anemia.
Summary
Applying Patient Blood Management concept to the trauma patient is possible and efficacious.
Antihyperfibrinolytics such as tranexamic acid, point-of-care testing and coagulation algorithms with the use
of factor concentrates allow a reduction of the number of transfusions, the costs and will likely ameliorate
outcome of major trauma patients.
Keywords
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INTRODUCTION
Trauma-associated bleeding leading to death has
been reported in up to 40% of all casualties in
civilian trauma centers [1,2,3
&&
]. Furthermore, it is
assumed that up to one-quarter of trauma-associ-
ated deaths might be preventable if early and rapid
control of blood loss and coagulopathy is estab-
lished [4,5
&&
]. Injuries leading to exsanguination
are to be located in the majority of the cases in
the thorax, abdomen and pelvis [6]. In addition,
prognosis of these patients is worse when coagul-
opathy is present at hospital admission [7–11]. For
this reason, early, aggressive, and rapid hemostatic
interventions are the key to prevent exsanguination
and avoid or minimize massive transfusion require-
ments [3
&&
].
Since 2010 theWorld Health Organization urges
member states to utilize transfusion alternatives and
develop individualized Patient Blood Management
Programs in order to reduce transfusion needs.
The three pillars of Patient Blood Management con-
sist of: ‘detection and treatment of preoperative
anemia, reduction in perioperative red blood cell
loss, and harnessing and optimizing the patient-
specific physiological reserve of anemia (includ-
ing restrictive hemoglobin transfusion triggers)’
[12
&
,13
&
,14
&&
,15
&
,16
&&
].
The first pillar is obviously not applicable in
the context of trauma, but the second and third
pillars are to be used also in the case of trauma.
Standard coagulation tests are used widely to
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identify trauma-induced coagulopathy but the
value of these tests has been challenged in recent
years. Routine coagulation tests were not developed
to identify bleeding in trauma. Furthermore these
tests are neither predictive for bleeding nor
validated for use in patients with major trauma
[17]. For this reason point-of-care devices, such as
rotational thromboelastometry (ROTEM, TEM
Innovations GmbH, Munich, Germany) or throm-
boelastography (TEG, Haemonetics Corp, Niles, IL,
USA), are used increasingly to treat bleeding in
trauma and are actually recommended to assist in
characterizing the coagulopathy and guide the
hemostatic therapy [3
&&
,18–21,22
&&
].
The purpose of this review is to highlight the
use of tranexamic acid, point-of-care testing,
algorithm-based treatment of trauma-associated
coagulopathy with factor concentrates to reduce
blood loss and transfusion requirements in order
to improve outcome. In addition, the management
of patients on new oral anticoagulants, drugs with
renewed interest and the tolerance of relatively low
hemoglobin levels in the context of trauma will be
discussed.
TRANEXAMIC ACID
In 1950, Okamoto et al. [23] described for the first
time the lysin derivate tranexamic acid (trans-4-
aminomethylcyclohexane-1-carboxylic acid, TXA)
that inhibits the action of plasmin. The use of
TXA showed a significant blood sparing effect in
elective surgery [24]. In 2010, the CRASH-2 Study
was the first randomized, placebo-controlled trial to
investigate TXA use in trauma. Application of TXA
to adult trauma patients in the emergency depart-
ment reduced all-cause mortality from 16.0 to
14.5% (P¼0.0035) and the risk of death due to
blood loss from 5.7 to 4.9% (P¼0.0077). The dosing
regimen was 1 g intravenously (i.v.) over 10min
followed by an infusion of 1 g over 8h. Expected
severe side-effects, in particular thrombotic events
such asmyocardial infarction and vascular occlusive
events were specifically assessed and found to occur
less frequently in the tranexamic acid group [25].
This study led to a worldwide increased scientific
interest for this antifibrinolytic drug (2009: 84
PubMed listed publications, January–October
2013: 229 publications. Keyword: tranexamic acid).
Recent studies review dose, timing of appli-
cation, exact indication and potential contraindica-
tions or adverse events of TXA use in trauma
patients. Grassin-Delyle et al. [26
&
] proposed a dos-
ing scheme of TXA based upon a pharmacokinetic
open two-compartment model with linear elimin-
ation. This implicates bolus application with con-
tinuous infusion of TXA. The validity for trauma
patients may be limited as the calculations were
made with children on cardiopulmonary bypass.
A systematic review of 104 randomized trials found
that the highly significant reduction of surgical
blood loss was largely independent of the i.v. TXA
doses from 5.5 to 300mg/kg. The authors conclude
that a total dose of 1 g is sufficient for most adult
patients [27,28
&&
].
In the prehospital setting 40 trauma patients
received TXA: 55% of the victims had penetrating
injuries, 45% had blunt trauma. The authors con-
cluded that prehospital administration of TXA at
the site of injury is feasible and that no direct
adverse drug events were observed [29
&&
]. However,
the study design and sample size did not allow
assessing patient’s outcome [29
&&
]. The re-analysis
of the CRASH-2 data showed that early TXA admin-
istrationwithin 1h of arrival in the emergency room
significantly reduced the risk of death due to bleed-
ing from 7.7 to 5.3% and from 6.1 to 4.8% when
given within 1–3h. Later administration resulted in
an increasedmortality due to bleeding (4.4 vs. 3.1%)
[30]. Moreover, the use of TXA has been shown to be
highly cost-effective [31
&&
].
TXA had also been successfully introduced in
military treatment algorithms. Despite greater
Injury Severity Scores after suffering combat inju-
ries, mortality was lowest for patients receiving cry-
oprecipitate and TXA (11.6%, n¼168) and TXA only
(18.2%, n¼148) compared with cryoprecipitate
alone (21.4%, n¼258) or no cryoprecipitate/TXA
(23.6%, n¼758). In addition, a systematic Cochrane
review provides evidence that TXA reduces blood
transfusions in patients requiring emergency or
urgent surgery [32
&
].
On the basis of WHO data and systematic liter-
ature review, Ker et al. [28
&&
] estimated that approxi-
mately 400000 trauma patients die in hospital due
to bleeding. They calculated that approximately
128000 deaths might be averted if these patients
received TXA within 1–3h of injury.
KEY POINTS
 The second and third pillar of Patient Blood
Management Programs can be applied in the setting of
trauma patients to reduce the use of blood products.
 The use of new oral anticoagulants is a new challenge
in trauma, as reversal of these drugs is difficult and
partially impossible.
 Tranexamic acid is becoming one of the key drugs to
reduce bleeding and reduce mortality in trauma
patients.
Trauma and transfusion
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In accordance with the European trauma
treatment guideline for the management of
bleeding and coagulopathy following major
trauma, ‘we emphasize that the first dose of TXA
should be given to all patients with trauma and
significant bleeding prehospitally at the scene of
accident or at the latest within 3h after the initial
trauma’ [3
&&
].
POINT-OF-CARE TESTING
In trauma, coagulopathy is common and multifac-
torial. Early recognition and treatment is likely
to reduce blood loss, the use of blood products,
and morbidity and mortality [3
&&
,33,34]. In recent
publications, transfusion algorithms guided
goal-directed transfusion (Fig. 1) therapy based on
laboratory variables and point-of-care testing were
described [3
&&
,35]. Thromboelastography and
thromboelastometry both measure and graphically
display the changes in viscoelasticity at all stages of
the developing and resolving clot, and provide the
first results within 5–10min, whereas laboratory
values take from 30min and up to 90min delaying
treatment in patients [36]. The method of the
ROTEM has been described in detail elsewhere [37].
To monitor coagulation in the trauma patient,
various tests are available including International
Normalized Ratio, aPTT, thrombin time, fibrinogen
testing (often by the Clauss method) [38], platelet
count, platelet function testing, and factor XIII and
FVIII determination. Proof-of-concept monitoring
of blood coagulation at the bedside is not only
desirable, but is becoming increasingly recom-
mended [3
&&
].
ACUTE ANEMIA
In contrast to routine cases, trauma patients under-
going surgery are generally not accessible for pre-
operative correction of anemia. However, severe
anemia (hemoglobin as low as 14 g/l) can be sur-
vivedwithout squeal, evenwithout allogeneic blood
transfusion [39]. Nevertheless, the European trauma
treatment guidelines recommend a hemoglobin
target range of 70–90g/dl [3
&&
].
In a recent trial, pigs were randomized into three
different groups and hemodiluted with hydroxy-
ethyl starch comparing no hemodilution vs. hemo-
globin of 4.0 g/dl and vs. the critical hemoglobin
level of 2.7 g/dl. In the hemodiluted state, 10mg/kg
of pimonidazole was injected, which forms protein
adducts in hypoxic cells. Interestingly, metabolic
parameters and oxygen consumption did not show
that tissue oxygenation was restricted before reach-
ing a hemoglobin level of 2.7 g/dl. Kidneys and
skeletal muscle showed enhanced pimonidazole
binding and vascular endothelial growth factor
expression at a hemoglobin level of 4 g/dl. Other
organs like heart, brain and liver showed no signs of
tissue hypoxia at hemoglobin levels of 4 g/dl. Acute
anemia tolerance is thus organ specific and needs to
be further elucidated [40
&&
].
Another interesting finding was made by Pape
et al. [41
&
] showing that deep neuromuscular
blockade increases the tolerance of acute normo-
volemic anemia. The possible mechanism seems to
involve a reduction of skeletal muscular oxygen
consumption for the benefit of vital organs.
Neuromuscular blockade therefore might play an
important role in the treatment of trauma victims
as critical levels of hemoglobin may be better
tolerated.
COAGULATION FACTOR CONCENTRATES
The transfusion of fresh frozen plasma (FFP) leads to
adverse effects such as an increased mortality,
multiple organ failure, risk of infection, lung injury
and immunomodulation [42,43
&
]. The effectiveness
of FFP compared with fibrinogen concentrate
regarding clinical endpoints as blood loss, transfu-
sion requirements, hospital length of stay, survival
and plasma fibrinogen concentration is favorable
for fibrinogen concentrates [44]. In patients with
massive transfusion, the use of FFP or fibrinogen is
indicated according to the European trauma Guide-
lines. If FFP is used, a plasma : red blood cell ratio of
least 1 : 2 is suggested. However, plasma transfusions
are to be avoided in patients without substantial
bleeding [3
&&
].
In many bleeding situations, including trauma,
fibrinogen is the first coagulation factor to become
critically low. Early testing for fibrinogen concen-
tration and specially for fibrinogen activity has been
proposed and implemented in many centers
[3
&&
,35,45–48].
In addition, target levels of fibrinogen concen-
trations for trauma patients have been defined at
1.5–2.0 g/l in the European Trauma Treatment
Guidelines [3
&&
]. As fibrinogen is a central element
of hemostasis, achieving these target levels is
important. Administering fibrinogen concentrates
is advantageous over FFP transfusion because the
fibrinogen concentration in FFP is highly variable
and rather low with 2g/l on average [49]. Therefore,
large volume transfusions of FFP would be necessary
to effectively increase the fibrinogen concentration,
and achieving the target fibrinogen concentration
of 1.5–2.0 g/l is virtually impossible given the
average fibrinogen concentration of 2g/l. When
replacing most FFP transfusions with fibrinogen
Applying ‘Patient Blood Management’ in trauma Theusinger et al.
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concentrate, monitoring factor XIII levels is
advisable after the replacement of approximately
50% of the blood volume; in addition, a 60%
factor XIII activity level is to be maintained with
the administration of factor XIII concentrate
[35,50–52].
Apart from single-factor concentrates, prothrom-
bin complex concentrates (PCC) are also part of
factor-based algorithms [35,46–48,53,54]. Individual
PCCs differ regarding their factors contained, their
relativecomposition, and their thromboticpotential.
In general, PCCs are used for the reversal of oral
Diagnostic Intervention
Preoperative history
ROTEM analysis Target values
ROTEM after anesthesia induction
1.       Drugs affecting coagulation
          -         Antiplatelet drugs
          -         Heparin
          -         Oral anticoagulation (Vit. K antagonists),
                     Xa antagonists, IIa antagonists
2.       Coagulation status?
3.       HIT II?
-         Transplant surgery
-         Cardiac and vascular surgery
-         Difficult cancer surgery
-         Liver insufficiency
-         Intra-abdominal sepsis
-         Emergency room entry
-         Normothermia (temp > 35°C)
-         Normocalcaemia (Ca > 1.15 mmol/l)
-         No acidosis (pH > 7.2)
-         Hematocrit > 0.21
-         Hypotension (MAP 55–60 mmHg)
Crystalloid and/or colloid volume substitution
-         EXTEM, INTEM, FIBTEM, APTEM
-         HEPTEM in heart and vascular surgery
FIBTEM < 7 mm
Blood loss > 50% with diffuse bleeding
Fibrinogen 2–4 g i.v. (maximal 3x2g), after a total of 6 g give
FXIII
INTEM (CT and CFT prolonged) and HEPTEM normal
or
ACT pathological and heparinase ACT normal
Protamine sulfate 1:1 to heparin
crystalloid and colloid volume substitution
Tranexamic acid
                     -         15 mg/kg body weight as bolus iv
                     -         1–2 mg/kg/h during surgery iv as perfusion
EXTEM/INTEM :
Decrease of MCF after maximum was reached
Ongoing diffuse bleeding
Ongoing diffuse bleeding
4 factor prothrombin complex 1000–2000 IU
                      -         Factor II, VII, IX and X
Depending on the patients’ body weight
If massive diffuse bleeding continues and
In case of massive transfusion Target hematocrit 0.21–0.24
EXTEM/INTEM MCF < 40 mm
APTEM :   normal
Hyperfibrinolysis
Quick’s value < 30% and
Factor V > 20%
or
EXTEM/INTEM: CT, CFT prolonged
Treated acidosis
Treated hypothermia
Treated hypocalcaemia
Hematocrit: 0.21–0.24
Excluded DIC
Fibrinogen was substituted
Platelets > 50 000/µl (> 100 000/µl in cardiac surgery or in
patients suffering from traumatic brain injury)
Recombinant factor VIIa
60 µg/kg body weight
A second dose of 60 µg/kg body weight can be given again
after 2–4 hours, if bleeding has not completely stopped.
CT EXTEM/INTEM normal
MCF FIBTEM < 7 mm
Hematocrit > 0.21
Fibrinogen up to 6 g, followed by Factor XIII 15 U/kg body weight
crystalloid and colloid volume substitution
MCF FIBTEM > 7 mm
Platelets < 50 000/µl (< 100 000/µl in cardiac surgery
or in patients suffering from traumatic brain injury)
Platelet concentrates
Coagulation test incl. F XIII, F V, INR, PT, aPTT
Target of Factor XIII: > 60% (Factor XIII 15  U/kg body weight)
Target of Factor V: > 20% (in particular in liver insufficiency
/trauma or intra-abdominal sepsis: 2–4 U FFP)
FIGURE 1. Third version of the transfusion algorithm of the University Hospital of Zu¨rich 2013, Switzerland. BW¼body
weight (modified according to [35], with permission of Lippincott Williams & Wilkins).
Trauma and transfusion
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anticoagulants [55]. The use of PCC is also suggested
by the update of the European Trauma Guidelines in
2013 if the initiation of clot formation is prolonged
in ROTEM [3
&&
]. PCC should be used only within
strict algorithms, the dose should be small and repeat
doses should be given with caution to minimize
thrombotic risks [54].
Actual studies indicate that a high amount of
RBCs, FFPs and platelets can be saved without
additional risks for patients by using a coagulation
factor concentrate-based coagulopathy manage-
ment in trauma [56]. Based upon data from four
European countries (UK, Germany, Italy and
Switzerland), blood substitution and blood
products were calculated and found to account
for approximately 27% of all costs associated with
trauma care on the ICU [57]. The reduced fre-
quency of septic complications and organ failure
observed here that translated into trends toward
reduced days on ventilator while on ICU and
shorter overall in-hospital length of stays may also
contribute to cost reduction in acute trauma care
without increasing the risk for the individual
patient.
DRUGS WITH RENEWED INTEREST
Desmopressin (DDAVP:1-deamino-8-D-argininevas-
opressin, 0.3mcg/kg) enhances platelet adherence
and is the first choice in the treatment of bleeding
patients with quantitative deficiency (type 1) and
some with qualitative defects (type 2) of von Wille-
brand factor [58,59]. Patients treated with aspirin,
ADP receptor inhibitors such as clopidogrel could
benefit from point-of-care testing to assess the indi-
vidual efficacy of desmopressin treatment [60].
Furthermore, the European Trauma Guidelines
suggest that patients treated with aspirin only may
benefit from a single dose of desmopressin [3
&&
].
Should the treatment with desmopressin be insuffi-
cient, transfusing platelets is the ultimate option.
Other antiplatelet drugs such as ticagrelor might
not be easily reversed with desmopressin and even
platelet transfusion may be relatively ineffective
[3
&&
,61
&&
].
NEW DRUGS
New oral anticoagulants acting as direct thrombin
(dabigatran) and factor Xa inhibitors (apixaban and
rivaroxaban) are now encountered also in the bleed-
ing trauma patient. Experience and treatment
options are limited.
There are reports of continuous bleeding after
trauma, in emergency surgery and in spontaneous
intracerebral hemorrhage [62
&
–64
&
]. This is probably
not because of the higher risk of bleeding per se but to
the persistence of effective plasma levels of the anti-
coagulatory substances [65
&
].
In healthy volunteers, a high dose (50U/kg) of
nonactivated PCC was able to completely reverse
antifactor Xa effects on laboratory parameters due to
rivaroxaban [66].
The use of activated factor VII to treat bleeding
under new oral anticoagulants is off label. Only
ex-vivo and in-vitro studies exist, showing theore-
tical and limited effect [67,68
&
] with case reports of
successful hemostatic treatment [69]. Hemodialysis
was reported to be effective for dabigatran removal
[70
&
,71]. Because of the high volume of distri-
bution, Chang et al. [72], however, saw a rebound
of dabigatran plasma levels after discontinuation of
dialysis.
Convincing clinical evidence for the reversal of
action of the new oral anticoagulants is lacking; no
studies evaluating the clinical success and the
possible thrombotic adverse events exist to date.
Immediate discontinuation of the anticoagulant is
mandatory. Activated charcoal is indicated for the
absorption of dabigatran within 2h after ingestion
[73].
Specific antagonists for factor Xa mediated anti-
coagulation are needed for immediate reversal in the
bleeding patient. R-Antidote (PRT064445) may be a
potential candidate and is currently under investi-
gation [74].
CONCLUSION
Applying the second pillar of Patient BloodManage-
ment to the trauma patient is possible and highly
efficacious. Antihyperfibrinolytics such as tranexa-
mic acid, point-of-care testing and coagulation
algorithms with the use of factor concentrates allow
a reduction of the number of transfusions, the costs
and will likely ameliorate outcome of major trauma
patients.
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